ForPatients
by Roche

Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Trial Status	Trial Runs In	Trial Identifier
Recruiting	3 Countries	NCT05927571 2023-504657-13-00 GO43979

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II dose (RP2D) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT05927571 2023-504657-13-00 GO43979
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years	No